Defining vitamin D status using multi-metabolite mathematical modelling: A pregnancy perspective

C.H.L. Beentjes, J.P. Taylor-King, A. Bayani, C.N. Davis, J.L. Dunster, S. Jabbari, G.R. Mirams, C. Jenkinson, M.D. Kilby, M. Hewison, J.A. Tamblyn

Mathematical Institute, University of Oxford, Oxford, UK
Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB3 OAS, UK
Institute of Molecular Systems Biology, Department of Biology, ETHZ, CH-8093, Zurich, Switzerland
Department of Physics and Mathematics, School of Science and Technology, Nottingham Trent University, Nottingham, UK
MathSys CDT, Mathematics Institute, University of Warwick, Coventry, UK
Institute for Cardiovascular and Metabolic Research, University of Reading, UK
School of Mathematics and Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK
Centre for Mathematical Medicine & Biology, Mathematical Sciences, University of Nottingham, UK
Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
Centre for Women’s & Newborn Health, Birmingham Health Partners, Birmingham Women’s & Children’s Foundation Hospital, Edgbaston, Birmingham, UK
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK
Fetal Medicine Centre, Birmingham Women’s & Children’s Foundation Trust, Edgbaston, Birmingham, UK

Abstract

Vitamin D deficiency is linked to adverse pregnancy outcomes such as pre-eclampsia (PET) but remains defined by serum measurement of 25-hydroxyvitamin D3 (25(OH)D3) alone. To identify broader changes in vitamin D metabolism during normal and PET pregnancies we developed a relatively simple but fully parametrised mathematical model of the vitamin D metabolic pathway.
The data used for parametrisation were serum vitamin D metabolites analysed for a cross-sectional group of women (n = 88); including normal pregnant women at 1st (NP1, n = 25) and 3rd trimester (NP3, n = 21) and pregnant women with PET (n = 22), as well as non-pregnant female controls (n = 20). To account for the effects various metabolites have upon each other, data were analysed using an ordinary differential equation model of the vitamin D reaction network. Information obtained from the model was then also applied to serum vitamin D metabolome data (n = 50) obtained from a 2nd trimester pregnancy cohort, of which 25 prospectively developed PET.

Statistical analysis of the data alone showed no significant difference between NP3 and PET for serum 25(OH) D3 and 24,25(OH)2D3 concentrations. Conversely, a statistical analysis informed by the reaction network model revealed that a better indicator of PET is the ratios of vitamin D metabolites in late pregnancy. Assessing the potential predicative value, no significant difference between NP3 and PET cases at 15 weeks gestation was found. Mathematical modelling offers a novel strategy for defining the impact of vitamin D metabolism on human health. This is particularly relevant within the context of pregnancy, where major changes in vitamin D metabolism occur across gestation, and dysregulated metabolism is evidenced in women with established PET.

**Keywords**

Vitamin D; Pregnancy; Preeclampsia; Metabolome; Mathematical model

1 **Introduction**

Sub-optimal serum levels of 25-hydroxyvitamin D3 (25(OH)D3) appear to be particularly prevalent in pregnant women [1,2], prompting association studies linking maternal 25(OH)D3 status and adverse events of pregnancy [3]. These include pre-eclampsia (PET) [4–6], small for gestational age babies [7], bacterial vaginosis [8], and gestational diabetes mellitus [9,10]. However, in recent years a much broader role for vitamin D in human pregnancy has been proposed, incorporating effects on female reproductive health [11,12], male reproductive health [11,13], fetal development [14,15], fetal programming [16], and offspring health [17,18]. In humans, vitamin D supplementation of pregnant women has been carried out to investigate effects on preterm birth [19] and neonatal health [18].

It is still unclear whether vitamin D-deficiency during pregnancy is simply a manifestation of the broader prevalence of low vitamin D status in populations across the globe, or whether this reflects a normal physiological drop in 25(OH)D3 concentrations during pregnancy, or if pregnancy is a stress test which can exacerbate and unmask pathological vitamin D deficiency. Whatever the case, it is important to recognise that, to date, studies have relied on measurement of a single parameter to define optimal vitamin D in pregnancy – namely serum levels of 25(OH)D3, the major circulating form of vitamin D. We have hypothesized that measurement of total serum concentrations of 25(OH)D3 alone provides only a limited view of vitamin D status, particularly in pregnancy where significant changes in vitamin D physiology occur from early gestation [20]. This includes changes in the serum
carrier vitamin D binding protein (DBP) during pregnancy [21] which may influence the bioavailability of unbound or DBP-bound 25(OH)D3 [22].

During pregnancy there is also a dramatic rise in maternal circulating concentrations of the active hormonal form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D3) from the 1st trimester of gestation [23]. Thus, the impact of vitamin D during pregnancy may be better defined by analysis of multiple serum vitamin D metabolites – the vitamin D metabolome. In women with PET we have previously reported significant dysregulation of multiple vitamin D metabolic pathways in the 3rd trimester of pregnancy, with decreased serum 1,25(OH)2D3 levels and enhanced catabolic 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) and 3-epi-25(OH)D3 concentrations observed for women with PET [20]. Conversely, in a study of pregnant women in the 1st trimester of pregnancy who subsequently progressed to normal or PET pregnancies we did not observe any significant variations in serum vitamin D metabolites between normal and PET pregnancies [24]. The aim of the current study was to develop a mathematical model of the serum vitamin D metabolome to provide an improved statistical analysis for screening for adverse events in pregnancy, such as PET, by identifying markers of vitamin D function and disease based on analysis of multiple vitamin D metabolites. Specifically, we aimed to detect a signal within vitamin D metabolite data recorded both in early (1st trimester) and late (3rd trimester) pregnancy, to allow classification of cases into high and low risk of PET. The study found that, rather than considering individual metabolite levels, inspection of specific ratios of these metabolites (as determined by the mathematical model) was a more informative predictive measure. Implementing data from a larger cohort of patients will transform this study from proof of concept into a strong predictive screening tool for PET. Though we have utilised data specifically with pregnancy in mind, the approach presented provides a novel analytical tool for the study of vitamin D metabolites more generally in human health and disease.

2 Materials and methods

2.1 Human pregnancy vitamin D metabolite datasets

Serum vitamin D metabolite data obtained from two distinct sets of pregnant women was utilised to ascertain the accuracy of each statistical approach (one considering individual metabolite levels, the other their ratios). The first group of women were from a cross-sectional pregnancy study which included 3 groups of pregnant women booked in the West Midlands, UK (i) first trimester uncomplicated pregnancies (8–13 weeks) (NP1; n = 25), (ii) healthy 3rd trimester pregnancies (> 37 weeks) (NP3; n = 21) and (iii) third trimester pregnancies complicated by PET (PET; n = 22). A healthy non-pregnant female ‘control’ group (n = 20) was also recruited for comparative serum vitamin D analysis as described in detail previously (West Midlands, Edgbaston REC (14/WM/1146 RG_14-194 [09.12.2016 approval]) (Table 1) [20].

For the second group of pregnant women, serum samples were purchased from the SCOPE (Screening for Pregnancy Endpoints) Ireland study (n = 50) (Clinical Research Ethics Committee of the Cork Teaching Hospital: ECM5 (10) [05.02.08 approval]) [24]. As previously described, sera samples from n = 50 low-risk nulliparous pregnant women taken at 15 weeks gestation (2nd trimester) were analysed. Of these, n = 25 prospectively
developed PET and n = 25 were selected as normotensive controls matched for maternal age, ethnicity and body mass index (BMI) (Table 1) [24]. Vitamin D metabolites were extracted from serum for LC–MS/MS analysis and measured as described previously [20,24,25]. Serum concentrations were obtained as outlined in Supplemental Table 1 and Supplemental Table 2.

2.2 Analysis of serum vitamin D metabolites

Analysis of serum concentrations of vitamin D metabolites (25(OH) D3, 3-epi-25(OH)D3, 1,25(OH)2D3 and 24,25(OH)2D3) was performed using previously reported liquid chromatography-tandem mass spectrometry (LC–MS/MS) methods [20,25]. In brief, samples were prepared for analysis by protein precipitation and supported liquid-liquid extraction. Analysis of serum was performed on a Waters ACQUITY ultra performance liquid chromatography coupled to a Waters Xevo TQ-S mass spectrometer. The LC–MS/MS method was validated based on US Food and Drug Administration guidelines for analysis of these metabolites, with CVs for each vitamin D metabolite analysis is shown in Table 2.

2.3 Regression analysis of vitamin D metabolite data across pregnancy

Serum vitamin D metabolite data from the West Midlands healthy pregnant (NP1 and NP3) and non-pregnant cohorts were first assessed by (linear) robust regression analysis to estimate the relationship between metabolome concentrations and gestation progression. This was performed using iteratively reweighted least squares with a bi-square weighting function using the MATLAB Curve Fitting Toolbox [26]. Robust regression using iterative re-weighting and non-standard weighting functions was chosen in favour to the more standard linear least-squares regression due to its capabilities to reliably handle outliers present in the raw data.

2.4 Principal component analysis

We began by applying a standard statistical analysis to the data independent of the mathematical model. We examined serum vitamin D metabolites for PET and healthy patient serum data from the SCOPE data for all patients where all five metabolites were available (N = 16 cases and N = 22 controls). Each metabolite value was normalised by multiplying by a scaling factor such that the mean for each normalised metabolite became equal to one. We then ran a principal component analysis (PCA) on the normalised dataset using the MATLAB ‘PCA’ function.

2.5 Linear classification analysis

The task of statistically classifying metabolite data into groups of healthy normotensive and PET women in an interpretable manner can be conveniently carried out using linear support-vector machines (SVMs) [26,27]. In this approach we find, given the training data, the best decision function which maps data to one of the two possible outcomes (healthy versus PET in our case) based on a linear combination of various features of the data, e.g. concentrations of different vitamin D metabolites. Using SVMs we can select the best possible linear decision function in terms of the accuracy of its predictions.
2.6 Kinetic mathematical model of vitamin D function

To account for the effects that vitamin D metabolites have on each other, initially the full chemical reaction network was modelled as a system of ordinary differential equations (in the next section this was reduced to a simpler but equally informative model that can be fully parametrised). As outlined in Table 3 and Fig. 1, variables were used to design a mathematical kinetic model for vitamin D physiology that incorporated the main cellular features of vitamin D metabolism and function; active, inactive and epimerised forms of vitamin D, as well as the key catabolic enzyme 24-hydroxylase [33,34]. These cellular variables were then used as a basis to model circulating vitamin D metabolites.

The metabolite network for vitamin D (Fig. 1) was mathematically interrogated by constructing a set of ordinary differential equations (ODEs), depicted in Tables 4 and 5, describing the time-dependent behaviour of vitamin D metabolites in the metabolite network. Based on saturation kinetics for vitamin D metabolism [28], we assumed that the conversion of 25(OH)D3 to 1,25(OH)2D3 follows Michaelis-Menten kinetics. For simplicity, and to facilitate model parametrisation, all other reactions were assumed to obey mass action kinetics (i.e. either they do not saturate or they do not saturate at the levels present in our data).

2.7 A reduced mathematical model of vitamin D function

As shown in Table 3, serum concentrations of 3-epi-1a,25(OH)2D3 and 24-hydroxylase enzyme activity were not measured in the current study. A reduced mathematical model of vitamin D metabolism was therefore designed by applying simplifying assumptions into the complete model given in Table 5, incorporating solely 25(OH)D3; 1,25(OH)2D3; 24,25(OH)2D3 and 3-epi-25(OH)D3; and their effective mutual interactions (Fig. 2). Firstly, we assume that levels of 24-hydroxylase are relatively constant so that we can assume conversion of 25(OH)D3 into 24,25(OH)2D3 and loss of 1,25(OH)2D3 from the system occur at a constant rate. Secondly, as we have no information regarding 3-epi-1a,25(OH)2D3, we can simply consider loss of 3-epi-25(OH)D3 and 1,25(OH)2D3 from the system to also capture their loss through conversion into 3-epi-1a,25(OH)2D3. Thus, these simplifying assumptions (that have the benefit of facilitating complete model parameterisation) should not have any untoward effect on overall data. The resulting reduced network has 8 unknown reaction constants and kinetic rate equations (see Tables 6 and 7) and can be described by a system of four ODEs (see Table 7). The equations can be fully parameterised (see Supplementary Information), and the steady states readily obtained (Table 8). These steady states are used to inform the statistical analysis in Section 3.4.

3 Results

3.1 Regression analysis of vitamin D metabolite data across pregnancy

Consistent with previous single metabolite data [24], regression analysis of data from the first group of pregnant women (West Midlands) showed increased serum concentrations of 1,25(OH)2D3 across normal pregnancy, but also revealed trends towards increased concentrations of 25(OH)D3, 3-epi-25(OH)D3, and 24,25(OH)2D3 from 1st to 3rd trimester (Fig. 3). Data for women with PET were not included in the regression analysis but are
shown for reference, providing further evidence for dysregulation of vitamin D metabolism in PET relative to healthy 3rd trimester pregnancies.

### 3.2 Principal component analysis (PCA)

Using strategies outlined in Section 2.4, PCA analysis was carried out to further interrogate serum vitamin D metabolite data from the West Midlands group. The first two components (PCA1 and PCA2) explained 74% of data variance but did not appear to separate PET and healthy 3rd trimester pregnancies (Supplemental Fig. 1). It was possible that another classifier could distinguish the normal and PET groups based on the remaining variation, or that a non-linear projection was required. To investigate these possibilities, we ran multiple classification algorithms using the MATLAB Classification Toolbox [32], however no strong classifiers were identified. We therefore utilised two linear classifier analyses: one independent from the mathematical model and one informed by the mathematical model.

### 3.3 Strategy 1: linear classifier analysis of metabolite data

Using data from the West Midlands group and 2nd trimester data from the SCOPE group we investigated a possible linear classifier strategy for defining normal healthy and PET pregnancies based on serum vitamin D metabolites. This approach aimed to delineate control/healthy normotensive and case/PET pregnant women by using a data dividing plane, as illustrated in Fig. 4. The dividing plane found is the best possible given the data in this study. A one-dimensional linear classifier specifies a single criterion for a single metabolite to predict whether the data represents control or case. A two-dimensional classifier, as illustrated in Fig. 4, sets combined criterion for two metabolites. For example, the threshold for 3-epi-25(OH)D3 increases as 25(OH)D3 increases and vice versa. For a combination of more than two metabolites the linear classifier generalises to provide a criterion based on the combined metabolite data. The efficacy of the linear classifiers is determined by the accuracy of the classification (percentage of correct classifications on the data set). Only classifiers achieving significantly > than 50% accuracy were of interest.

From earlier work [24] we postulated that individual vitamin D metabolite data cannot accurately predict future risk of PET onset. As shown in Fig. 4, individual metabolite classifiers did not reach accuracies > 68%. However, combining the data of four metabolites (25(OH)D3, 3-epi-25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3) for a single and finding the best four-dimensional linear classifier increased the accuracy of distinguishing between PET and normal pregnancies to 74%, suggesting that measurement of multiple vitamin D metabolites has the potential to be a more accurate representation of vitamin D ‘status’.

### 3.4 Strategy 2: linear classifier analysis on metabolite ratios informed by the mathematical model

An alternative strategy to analyse serum vitamin D metabolite data in pregnancy is to consider metabolite ratios. Rather than calculating all possible combinations of vitamin D metabolites to form pairwise ratios, informative ratios, designated as $\alpha$, $\beta$, and $\gamma$ (Table 9), were determined directly from the steady state relationships outlined in the reduced kinetic model for vitamin D metabolism ((3.1b)–(3.1d), Table 8).
Using the estimated Michaelis constant $K$ (Supplementary Table 4) individual patient data were transformed (non-linearly) into three metabolite ratios (Table 9), reflecting the different major pathways in vitamin D metabolism. For example, rather than looking at isolated 3-epi-25(OH)D3 values, the concentration of epimerised 25(OH)D3 in relation to 25(OH)D3 was considered, encoded by ratio \( \beta \). This approach appears more informative than interpretation of single 3-epi-25(OH)D3 concentrations which alone do not help explain whether an increased intake of 25(OH)D3 determines downstream vitamin D metabolite concentrations, or whether it is the epimerisation pathway that is specifically upregulated.

The effect of transforming metabolite data into ratios before finding the best linear classifier was also assessed. This revealed significant improvement in the accuracy of classifiers. For example, solely utilising the 3rd trimester epimerisation ratio (3.2b) as the linear classifier, results in an accuracy of 72% in delineating between healthy and PET pregnancies. Combining metabolite ratios together resulted in an accuracy of 84% for the West Midlands 3rd trimester data. The high accuracy for the linear classifier based on the epimerisation ratio, $\beta$, alone suggests that changes in the vitamin D epimerisation pathway may be a marker of PET. Conversely, as illustrated in Fig. 5, the combined metabolite ratio analysis did not improve the overall accuracy of classification in the 2nd trimester SCOPE data.

4 Discussion

Vitamin D-deficiency has been linked to the pregnancy disorder PET, a condition that can increase morbidity and mortality in pregnant women, and their unborn and newborn babies. To date, studies of vitamin D and PET have focused on serum measurement of a single vitamin D metabolite, 25(OH)D3 despite the fact that pregnancy is characterised by distinct changes in vitamin D metabolism [29,30]. The metabolic pathway for vitamin D is relatively well-defined and multiple vitamin D metabolites are measurable from serum. Using data from pregnant and non-pregnant women, where concentrations of four of these metabolites have been measured, the principal aim of this study was to use a combination of data analysis and mathematical modelling to identify differences in vitamin D metabolism between normal and PET pregnancies. In particular, the data from 2nd trimester pregnant women in the SCOPE study investigated to determine whether the models we used could accurately classify healthy normotensive (control) and PET (case) pregnant women prior to the onset of PET symptoms based upon early 2nd trimester vitamin D metabolite data.

Mathematical modelling of metabolic networks can often lead to large numbers of ordinary differential equations governed by many parameters that are often neither measurable nor straightforward to estimate from experimental data. To address this, data from 3rd trimester pregnant women were utilised to develop a kinetic model of vitamin D metabolism incorporating 25(OH)D3, 3-epi-25(OH)D3, 1,25(OH)$_2$D3 and 24,25(OH)$_2$D3. From this we were able to reduce the full vitamin D network to include only these metabolites without disturbing the network shape surrounding them. In conjunction with literature values for half-life times this facilitated full parametrisation of the ordinary differential equation model of the reduced vitamin D network, an achievement that is rare in related mathematical models.
In the current study we compared two main modelling strategies, (i) linear classifier analysis using metabolite data and (ii) linear classifier analysis using metabolite ratios; the latter was motivated by analysis of our reduced kinetic model of vitamin D metabolism. It was shown that this permits more accurate classification of trends in vitamin D metabolism in normal and disease pregnancy compared to individual metabolite data analysis. Moreover, utilising combined metabolite ratios to reflect the interplay between the major metabolic pathways $1\alpha$-hydroxylation, epimerisation and 24-hydroxylation, a more accurate classification of 3rd trimester healthy controls and PET cases was obtained.

The high accuracy for the linear classifier based on the epimerisation ratio suggests changes in the epimerisation pathway of the vitamin D metabolism could be a marker of PET. Since this was only visible in the third trimester it appears changes in vitamin D metabolism are gradual and that significant dysregulation develops as a result of PET, rather than being a precursor to disease development, although it is important to recognise that the current study involved relatively small samples sizes.

5 Summary and future work

The current study describes a novel strategy for understanding the differences in vitamin D metabolism between pregnant and non-pregnant women and distinguishing those pregnant women who have developed the pregnancy disorder PET. A major limitation of the current study was the small sample numbers in both the 2nd trimester (SCOPE) and 3rd trimester (West Midlands) studies. Future studies will aim to collect data from larger diverse cohorts of women to improve the reliability of both the statistical analyses and the model parametrisation described in the current mathematical analysis. The aim of mathematical modelling in this fashion is to generate new hypotheses for variations in vitamin D metabolism during pregnancy. In turn this may help to identify novel intervention and supplementation strategies for both normal pregnancy and PET. However, the potential applications for this mathematical modelling strategy extend far beyond pregnancy, with clear opportunities for refining our overall approach to the assessment of vitamin D related health and disease.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the Engineering and Physical Sciences Research Council [grant numbers EP/L001101/1 and EP/G037280/1]; the Wellcome Trust [grant number 101222/Z/13/Z]; the Biotechnology and Biological Sciences Research Council [grant numbers BB/M021386/1, BB/M025888/1]; the British Heart Foundation [grant number PG/16/20/32074]; the NIH [grant number AR063910], Wellbeing of Women [grant number RFTF401].

This study was supported by funding from NIH to MH, a Royal Society Wolfson Merit Award to MH, Wellbeing of Women Research Training Fellowship to JAT, POEMS (Predictive modelling for healthcare technology through maths) and MSB-Net (UK Multi- Scale Biology Network). J.P.T-K. received funding from the EPSRC. C.H.L.B. received funding from the Clarendon Fund and New College, Oxford. G.R.M. gratefully acknowledges support from a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society. S.J. thanks the
BBSRC for support in the form of a New Investigator Research Grant. J.L.D. gratefully acknowledges support from the British Heart Foundation.

References

[1]. Hypponen E, Boucher BJ. Avoidance of vitamin D deficiency in pregnancy in the United Kingdom: the case for a unified approach in National policy. Br J Nutr. 2010; 104: 309–314. [PubMed: 20594390]

[2]. Bodnar LM, Simhan HN, Powers RW, Frank MP, Cooperstein E, Roberts JM. High prevalence of vitamin D insufficiency in black and white pregnant women residing in the northern United States and their neonates. J Nutr. 2007; 137: 447–452. [PubMed: 17237325]

[3]. Hypponen E, Cavadino A, Williams D, Fraser A, Verczkey A, Fraser WD, Lawlor D, Czeizel AE. Vitamin D and pre-eclampsia: original data, systematic review and meta-analysis. Ann Nutr Metab. 2013; 63: 331–340. [PubMed: 24603503]

[4]. Bodnar LM, Catov JM, Simhan HN, Holick MF, Powers RW, Roberts JM. Maternal vitamin D deficiency increases the risk of preeclampsia. J Clin Endocrinol Metab. 2007; 92: 3517–3522.

[5]. Mirzakhani H, Litonjua AA, McElrath TF, O’Connor G, Parritz A-Lee, Iverson R, Maones G, Strunk RC, Bacharier LB, Zeiger R, Hollis BW, et al. Early pregnancy vitamin D status and risk of preeclampsia. J Clin Invest. 2016; 126: 4702–4715. [PubMed: 27841759]

[6]. Baker AM, Haeri S, Camargo CA Jr, Espinola JA, Stuebe AM. A nested case control study of midgestation vitamin D deficiency and risk of severe preeclampsia. J Clin Endocrinol Metab. 2010; 95: 5105–5109. [PubMed: 20719829]

[7]. Bodnar LM, Catov JM, Zmuda JM, Cooper ME, Parrott MS, Roberts JM, Marazita ML, Simhan HN. Maternal serum 25-hydroxyvitamin D concentrations are associated with small-for-gestational age births in white women. J Nutr. 2010; 140: 999–1006. [PubMed: 20200114]

[8]. Bodnar LM, Krohn MA, Simhan HN. Maternal vitamin D deficiency is associated with bacterial vaginosis in the first trimester of pregnancy. J Nutr. 2009; 139: 1157–1161. [PubMed: 19357214]

[9]. Zhang C, Qiu C, Hu FB, David RM, Van Dam RM, Bralley A, Williams MA. Maternal plasma 25-hydroxyvitamin D concentrations and the risk for gestational diabetes mellitus. PLoS One. 2008; 3 e3753 [PubMed: 19015731]

[10]. Burris HH, Rifas-Shiman SL, Kleinman K, Litonjua AA, Huh SY, Rich-Edwards JW, Camargo CA Jr, Gillman MW. Vitamin D deficiency in pregnancy and gestational diabetes mellitus. Am J Obstet Gynecol. 2012; 207 (182) e181-188

[11]. Bollehuus Hansen L, Rehfeld A, de Neergaard R, Nielsen JE, Iversen LH, Boisen IM, Mortensen LJ, Lanske B, Almstrup K, Carlsen E, Berg AH, et al. Selection of high-quality spermatozoa may be promoted by activated vitamin D in the woman. J Clin Endocrinol Metab. 2017; 102: 950–961. [PubMed: 27977320]

[12]. Abadia L, Gaskins AJ, Chiu YH, Williams PL, Keller M, Wright DL, Souter I, Hauser R, Chavarro JE, Environment T. Reproductive Health Study. Serum 25-hydroxyvitamin D concentrations and treatment outcomes of women undergoing assisted reproduction. Am J Clin Nutr. 2016; 104: 729–735. [PubMed: 27465382]

[13]. Blomberg Jensen M, Gerner Lavaetz J, Andersson AM, Petersen JH, Nordkap L, Bang AK, Ekborn P, Joensen UN, Praetorius L, Lundstrom P, Boujida VH, et al. Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Hum Reprod. 2016; 31: 1875–1885. [PubMed: 27496946]

[14]. Weinert LS, Silveiro SP. Maternal-fetal impact of vitamin D deficiency: a critical review. Matern Child Health J. 2015; 19: 94–101. [PubMed: 24748216]

[15]. Mahon P, Harvey N, Crozier S, Inskip H, Robinson S, Arden N, Swaminathan R, Cooper C, Godfrey K. Low maternal vitamin D status and fetal bone development: cohort study. J Bone Miner Res. 2010; 25: 14–19. [PubMed: 19580464]

[16]. Hypponen E. Preventing vitamin D deficiency in pregnancy: importance for themother and child. Ann Nutr Metab. 2011; 59: 28–31.

[17]. Eyles D, Burne T, McGrath J. Vitamin D in fetal brain development. Semin Cell Dev Biol. 2011; 22: 629–636.
[18]. Litonjua AA, Carey VJ, Laranjo N, Harshfield BJ, McElrath TF, O’Connor GT, Sandel M, Iverson RE Jr, Lee-Paritz A, Strunk RC, Bacharier LB, et al. Effect of prenatal supplementation with vitamin D on asthma or recurrent wheezing in offspring by age 3 years: the VDAART Randomized Clinical Trial. JAMA. 2016; 315: 362–370. [PubMed: 26813209]

[19]. Wagner CL, Baggerly C, McDonnell S, Baggerly KA, French CB, Baggerly LA, Hamilton SA, Hollis BW. Post-hoc analysis of vitamin D status and reduced risk of preterm birth in two vitamin D pregnancy cohorts compared with South Carolina March of Dimes 2009-2011 rates. J Steroid Biochem Mol Biol. 2016; 155: 245–251. [PubMed: 26554936]

[20]. Tamblyn JA, Susarla R, Jenkinson C, Jeffery LE, Ohizua O, Chun RF, Chan SY, Kilby MD, Hewison M. Dysregulation of maternal and placental vitamin D metabolism in preeclampsia. Placenta. 2017; 50: 70–77. [PubMed: 28161064]

[21]. Barragry JM, Corless D, Auton J, Carter ND, Long RG, Maxwell JD, Switala S. Plasma vitamin D-binding globulin in vitamin D deficiency, pregnancy and chronic liver disease. Clin Chim Acta. 1978; 87: 359–365. [PubMed: 79455]

[22]. Powe CE, Seely EW, Rana S, Bhan I, Ecker J, Karumanchi SA, Thadhani R. First trimester vitamin D, vitamin D binding protein, and subsequent preeclampsia. Hypertension. 2010; 56: 758–763. [PubMed: 20733087]

[23]. Kumar R, Cohen WR, Silva P, Epstein FH. Elevated 1,25-dihydroxyvitamin D plasma levels in normal human pregnancy and lactation. J Clin Invest. 1979; 63: 342–344. [PubMed: 429557]

[24]. Tamblyn JA, Jenkinson C, Larner DP, Hewison M, Kilby MD. Serum and urine vitamin D metabolite analysis in early preeclampsia. Endocr Connect. 2018; 7: 199–210. [PubMed: 29217650]

[25]. Jenkinson C, Taylor AE, Hassan-Smith ZK, Adams JS, Stewart PM, Hewison M, Keevil BG. High throughput LC-MS/MS method for the simultaneous analysis of multiple vitamin D analytes in serum. J Chromatogr B. 2016; 1014: 56–63.

[26]. MATLAB. Curve Fitting Toolbox and Statistics and Machine Learning Toolbox. The MathWorks, Inc; Natick, Massachusetts, United States: 2018.

[27]. Shawe-Taylor J, Cristianini N. An Introduction to Support Vector Machines and Other Kernel-based Learning Methods. 2000.

[28]. Need AG, O’Loughlin PD, Morris HA, Coates PS, Horowitz M, Nordin BE. Vitamin D metabolites and calcium absorption in severe vitamin D deficiency. J Bone Miner Res. 2008; 23: 1859–1863. [PubMed: 18597633]

[29]. Liu NQ, Hewison M. Vitamin D, the placenta and pregnancy. Arch Biochem Biophys. 2012; 523: 37–47.

[30]. Zehnder D, Evans KN, Kilby MD, Bulmer JN, Innes BA, Stewart PM, Hewison M. The ontogeny of 25-hydroxyvitamin D(3) 1alpha-hydroxylase expression in human placenta and decidua. Am J Pathol. 2002; 161: 105–114. [PubMed: 12107095]

[32]. Jones KS, Schoenmakers I, Bluck LJ, Ding S, Prentice A. Plasma appearance and disappearance of an oral dose of 25-hydroxyvitamin D2 in healthy adults. Br J Nutr. 2012; 107: 1128–1137. [PubMed: 21896243]

[33]. Leeuwenkamp OR, van der Wiel HE, Lips P, van der Vijgh WJ, Barto R, Greuter H, Netelenbos JC. Human pharmacokinetics of orally administered (24R)-hydroxycalcidiol. Eur J Clin Chem Clin Biochem. 1993; 31: 419–426. [PubMed: 8399781]

[34]. Jongen M, van der Vijgh WJ, Netelenbos JC, Postma GJ, Lips P. Pharmacokinetics of 24,25-dihydroxyvitamin D3 in humans. Horm Metab Res. 1989; 21: 577–580. [PubMed: 2807147]
Figure 1. Network diagram for the kinetic model of vitamin D metabolism.
Reaction network structure for vitamin D metabolome model, including the metabolites 25-hydroxyvitamin D3 (25(OH)D3); C3-epimer hydroxyvitamin D3 (3-epi-25(OH)D3); 1,25-dihydroxyvitamin D3 (1,25(OH)2D3); 24,25-dihydroxyvitamin D3 (24,25(OH)2D3); C3-epimer 1,25-hydroxyvitamin D3 (3-epi-1α,25(OH)2D3); and the key enzyme vitamin D-24-hydroxylase (24-hydroxylase). Black arrows depict conversion steps and dotted lines indicate enzymatic interactions, numbers are defined in Table 4. Serum data was only available for the metabolites in red.
Figure 2. Network diagram of the reduced kinetic model for vitamin D metabolism. The network only contains chemicals with measured concentrations, 25-hydroxyvitamin D3 (25(OH)D3); C3-epimer 25-hydroxyvitamin D3 (3-epi-25(OH)D3); 1,25-dihydroxyvitamin D3 (1,25(OH)₂D3) and 24,25-dihydroxyvitamin D3 (24,25(OH)₂D3). Black arrows depict conversion steps, and their numbers are defined in Table 6.
Figure 3. Regression analysis of serum vitamin D metabolites across normal pregnancy.
Serum concentrations of 25-hydroxyvitamin D3 (25(OH)D3), C3-epimer 25-hydroxyvitamin D3 (3-epi-25(OH)D3), 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) according to week of pregnancy. Grey areas show the 95% confidence bands around fitted regression lines (black lines solid lines) and $R^2$ values for each regression are reported under their respective graphs. PET samples (3rd trimester) were not included in the regression but are shown for reference.
Figure 4. A two-dimensional linear classifier (dotted line) incorporating serum 3-epi-25(OH)D3 (y-axis) and 25(OH)D3 [nM] (x-axis) concentrations for the SCOPE (15 weeks of pregnancy) (left) and West Midlands (third trimester) data (right). The linear classifier classes serum data in the grey section as PET case and the remainder as being healthy pregnancies. False-positives and false-negatives are clearly visible and lead to a classification accuracy of only 56% (left) and 68% (right).
Figure 5. Accuracy of best linear classifiers of data.
Accuracy classification is shown for 2nd trimester (SCOPE) and 3rd trimester (West Midlands) data. A. Based on data for individual vitamin D metabolites, and combined vitamin D metabolites (diamonds). B. based on individual metabolite or combined metabolite ratios (diamonds). Reference baseline accuracy of 50% is indicated by dotted lines.
Table 1
Demographic summary and analysis of participants in West Midlands and SCOPE women analysed in this study.

The West Midlands group includes non-pregnant female controls, normal pregnant women (n = 20) at first (NP1, n = 25) and third trimester (NP3, n = 21) and women with PET (n = 22). The SCOPE group includes PET cases (n = 25) matched to normotensive controls (n = 25) for age, ethnicity and body mass index (BMI).

Total frequency (n) with percentage of total group (%), and median values with 25th-75th interquartile range (IQR) values were calculated as stated. Statistically significant variations and post hoc test analyses are summarised; A ANOVA; T t-test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

|                      | West Midlands | SCOPE          |
|----------------------|---------------|----------------|
|                      | Nonpregnant (n = 20) | NP1 (n = 25) | NP3 (n = 21) | PET (n = 22) | Post-hoc analysis | Normotensive controls (n = 25) | PET cases (n = 25) |
| Parity: nulliparous, total (%) | – | – | 3 (14.3%); 18 (81.8%); 4 (18.2%) | – | 25 (100.0%) | 25 (100.0%) |
| Maternal age, mean; SD, year | 36 | 27.8 | 33.6 | 28.1 | A Non-pregnant & NP1 (**); Non-pregnant & PET (*) | 30.5 | 30.5 |
| BMI, mean; SD, unit | – | 13.5 | 7.3 | 3.8 | 7.3 | 3.4 | 3.7 |
| Mean arterial blood pressure (MABP), mean; SD, unit | – | 27.8 | 8.1 | 28 | 6.1 | ns | 30.4 | 30.5 |
| Vitamin D supplements/day (400iu), total (%) | – | 88.2 | 85.3 | 111.9 | A NP1 & PET (**); NP3 & PET | 92.2 | 119.7**** |
| Positive smoking status, total (%) | 0 (0%) | 7 (33.3%) | 1 (4.55%) | ns | 9 (36.0) | 3 (12.0) |
| Gestational age at delivery, mean; SD, week | – | 10.1 | 39 | 36.7 | ns | 40.4 | 38.0**** |
| Birthweight, mean; SD, grams | – | 3521 | 2710 | 1121 | T NP3 & PET (**); NP3 & PET | 3717 | 3109 ** | 522.9 | 802 |
Table 2
Accuracy and precision data for vitamin D metabolite analyses.

Intra-day precision was calculated based on %RSD following the analysis of six replicates for each of the three concentration levels of each metabolite. Inter-day precision was performed over three days calculated based on %RSD following the analysis of six replicates for each of the three concentration levels of each metabolite per day for three days. Accuracy represents the percentage deviation from the true value and was calculated based on the analysis of six replicates of each concentration level for each metabolite.

| Compound     | Concentration (ng/mL) | Level | Precision (% RSD) | Accuracy (%) |
|--------------|-----------------------|-------|-------------------|--------------|
|              |                       |       | Intra-day         | Inter-day    |              |
| 25OHD3       | 0.500                 | Low   | 7.61              | 9.20         | 100.15       |
|              | 5.00                  | Medium| 10.68             | 7.45         | 91.34        |
|              | 20.00                 | High  | 4.18              | 4.93         | 106.84       |
| 3-Epi-25OHD3 | 0.188                 | Low   | 8.38              | 11.61        | 103.83       |
|              | 1.875                 | Medium| 8.41              | 6.10         | 111.74       |
|              | 7.500                 | High  | 3.20              | 5.25         | 97.45        |
| 1α,25(OH)2D3| 0.061                 | Low   | 9.64              | 8.20         | 111.80       |
|              | 0.750                 | Medium| 3.05              | 5.30         | 99.33        |
|              | 2.000                 | High  | 4.29              | 4.20         | 99.96        |
| 23R,25(OH)2D3| 1.00                  | Low   | 6.46              | 9.62         | 98.02        |
|              | 4.00                  | Medium| 9.31              | 9.17         | 98.56        |
|              | 8.00                  | High  | 4.49              | 10.85        | 96.71        |
| 24R,25(OH)2D3| 0.500                 | Low   | 6.19              | 8.13         | 98.62        |
|              | 4.00                  | Medium| 7.22              | 8.26         | 98.47        |
|              | 8.00                  | High  | 6.08              | 8.48         | 100.40       |
| 25OHD2       | 1.000                 | Low   | 10.59             | 9.58         | 96.47        |
|              | 2.500                 | Medium| 9.52              | 8.38         | 92.91        |
|              | 10.00                 | High  | 14.19             | 9.80         | 99.13        |
| 24OHD2       | 0.625                 | Low   | 9.26              | 7.07         | 99.11        |
|              | 1.000                 | Medium| 7.46              | 6.86         | 108.03       |
|              | 2.500                 | High  | 3.37              | 5.65         | 90.77        |
| 3-Epi-25OHD2 | 0.500                 | Low   | 11.11             | 8.20         | 114.80       |
|              | 1.875                 | Medium| 3.75              | 6.62         | 110.89       |
|              | 7.500                 | High  | 0.69              | 3.15         | 100.98       |
| 1α,25(OH)2D2| 0.075                 | Low   | 10.44             | 7.88         | 90.44        |
|              | 0.750                 | Medium| 4.08              | 7.60         | 93.19        |
|              | 2.000                 | High  | 5.34              | 3.63         | 102.87       |
| 1α,24(OH)2D2| 0.0630                | Low   | 8.45              | 10.91        | 96.30        |
|              | 0.625                 | Medium| 4.24              | 5.96         | 102.41       |
|              | 2.000                 | High  | 4.10              | 5.20         | 109.39       |
| 7αC4         | 0.375                 | Low   | 5.54              | 8.00         | 106.13       |
|              | 3.750                 | Medium| 9.81              | 8.71         | 96.07        |
|              | 15.00                 | High  | 7.85              | 8.20         | 98.55        |
Table 3
Metabolite variables used in the full vitamin D kinetic model.

Summary of the vitamin D metabolites and enzymes utilised in the full kinetic model with their abbreviation, functional description and measurement status included.

| Metabolite/enzyme variable | Abbreviation | Description                  | Measured |
|----------------------------|--------------|------------------------------|----------|
| 25-hydroxyvitamin D3       | 25(OH)D3     | storage pro-hormone vitamin D | ✓        |
| 1,25-dihydroxyvitamin D3   | 1,25(OH)2D3  | active vitamin D             | ✓        |
| 24,25 dihydroxyvitamin D3  | 24,25(OH)2D3 | inactive vitamin D           | ✓        |
| C3-epimer 25-hydroxyvitamin D3 | 3-epi-25(OH)D3 | epimer of pro-hormone vitamin D | ✓ |
| C3-epimer 1,25-hydroxyvitamin D3 | 3-epi-1α,25(OH)2D3 | epimer of active vitamin D | ✓ |
| vitamin D-24-hydroxylase   | 24-hydroxylase | catabolic enzyme            | ✓        |
Table 4
Reaction rate terms for the full kinetic model of vitamin D metabolism shown in Fig. 1.

Reaction numbers correspond to Fig. 1. Metabolites and enzymes with abbreviations are shown in Table 3. Vitamin D metabolite concentrations and the Michaelis constant $K$ are measured in nM. Non-catalytic rate constants ($k_3 - k_{14}$) and catalytic rate constants ($V_7, V_9$) are measured in d$^{-1}$ and nM$^{-1}$ d$^{-1}$ respectively (d = days). Base production constants ($P_{25(OH)D3}$ and $P_{24-hydroxylase}$) and maximal enzyme rate $a$ are measured in nM•d$^{-1}$.

| Reaction | Description                                                                 | Rate term                                      |
|----------|------------------------------------------------------------------------------|------------------------------------------------|
| 1        | Production of 25(OH)D3 from diet and sunlight                                | $P_{25(OH)D3}$                                |
| 2        | Conversion by 1α-hydroxylase of 25(OH)D3 to 1,25(OH)$_2$D3                  | $a[25(OH)D3]/(K + [25(OH)D3])$                |
| 3        | Epimerisation of 25(OH)D3 to 3-epi-25(OH)D3                                 | $k_3[25(OH)D3]$                               |
| 4        | Enzymatic conversion by 24-hydroxylase of 25(OH)D3 to 24,25(OH)$_2$D3       | $V_7[24 – hydroxylase]·[25(OH)D3]$             |
| 5        | Degradation of 25(OH)D3                                                      | $k_5[25(OH)D3]$                               |
| 6        | Conversion of 24,25(OH)$_2$D3 to calcitricic acid                           | $k_6[24,25(OH)_2D3]$                          |
| 7        | Enzymatic conversion by 24-hydroxylase of 1,25(OH)$_2$D3 to calcitricic acid | $V_7[24 – hydroxylase]·[1,25(OH)_2D3]$         |
| 8        | Conversion by 1α-hydroxylase of 3-epi-25(OH)D3 into 3-epi-1α,25(OH)D3       | $k_8[3 – epi – 25(OH)D3]$                      |
| 9        | Vitamin D Receptor (VDR) activation                                          | $k_9[1,25(OH)_2D3]$                           |
| 10       | Epimerisation of 1,25(OH)$_2$D3 to 3-epi-1α,25(OH)$_2$D3                    | $k_{10}[24,25(OH)_2D3]$                       |
| 11       | Vitamin D Receptor (VDR) activation                                          | $k_{11}[3 – epi – 25(OH)_2D3]$                |
| 12       | Enzyme production stimulated by 1,25(OH)$_2$D3                               | $k_{12}[1,25(OH)_2D3]$                        |
| 13       | Basal enzyme production                                                      | $P_{24-hydroxylase}$                          |
| 14       | Degradation of enzyme                                                        | $k_{14}[24 – hydroxylase]$                    |
Table 5
Kinetic equations representing the vitamin D metabolism model network depicted in Fig. 1.

Reaction terms $R_i$ for $i = 1, \ldots, 14$ correspond to the respective rate terms as given in Table 4. Variables whose concentrations are tracked in the model are concentrations of the vitamin D metabolites 25-hydroxyvitamin D3 (25(OH)D); C3-epimer 25-hydroxyvitamin D3 (3-epi-25(OH)D); 1,25-dihydroxyvitamin D3 (1,25(OH)$_2$D); 24,25-dihydroxyvitamin D3 (24,25(OH)$_2$D); C3-epimer 1,25-hydroxyvitamin D3 (3-epi-1α,25(OH)$_2$D); and the enzyme vitamin D-24-hydroxylase (24-hydroxylase).

\[
\begin{align*}
\frac{d[25(OH)D3]}{dt} &= R_1 - R_2 - R_3 - R_4 - R_5 \\
\frac{d[1,25(OH)_2D3]}{dt} &= R_2 - R_7 - R_9 - R_{10} \\
\frac{d[24,25(OH)_2D3]}{dt} &= R_4 - R_6 \\
\frac{d[3epi-25(OH)D3]}{dt} &= R_3 - R_8 \\
\frac{d[3epi-1,25(OH)_2D3]}{dt} &= R_8 + R_{10} - R_{11} \\
\frac{d[24-hydroxylase]}{dt} &= R_{12} + R_{13} - R_{14}
\end{align*}
\]
### Table 6
Kinetic rate terms for the reduced kinetic model of vitamin D metabolism in Fig. 2.

Reaction numbers correspond to numbered interactions as shown in Fig. 2. Metabolites are listed with abbreviations in Table 3. Concentrations and Michaelis constant $K$ are measured in nM. Non-catalytic rate constants ($k_3 - k_8$) are measured in d$^{-1}$. Base production constants ($P_{25(OH)D3}$) and maximal enzyme rate ($a$) are measured in nM d$^{-1}$.

| Reaction | Description                                           | Rate term                                      |
|----------|-------------------------------------------------------|-----------------------------------------------|
| 1        | Production of 25(OH)D3 from diet and sunlight         | $P_{25(OH)D3}$                               |
| 2        | Conversion by 1α-hydroxylase of 25(OH)D3 to 1,25(OH)$_2$D3 | $a[25(OH)D3]/(K + [25(OH)D3])$               |
| 3        | Epimerisation of 25(OH)D3 to 3-epi-25(OH)D3          | $k_3[25(OH)D3]$                              |
| 4        | Conversion by 24-hydroxylase of 25(OH)D3 to 24,25(OH)$_2$D3 | $k_4[25(OH)D3]$                              |
| 5        | Degradation of 25(OH)D3                              | $k_5[25(OH)D3]$                              |
| 6        | Enzymatic conversion of 24,25(OH)$_2$D3 to calcitroic acid | $k_6[24,25(OH)_2D3]$                         |
| 7        | Effective degradation of 1,25(OH)$_2$D3              | $k_7[1,25(OH)_2D3]$                         |
| 8        | Effective degradation of 3-epi-25(OH)D3              | $k_8[3−epi−25(OH)D3]$              |
Table 7
Kinetic equations for the reduced vitamin D metabolism model network depicted in Fig. 2.

Reaction terms $R_i$, for $i = 1, \ldots, 8$ correspond to the respective rate equations as depicted in Table 6. Concentrations are for the vitamin D metabolites 25-hydroxyvitamin D3 (25(OH)D3); C3-epimer 25-hydroxyvitamin D3 (3-epi-25(OH)D3); 1,25-dihydroxyvitamin D3 (1,25(OH)$_2$D3) and 24,25-dihydroxyvitamin D3 (24,25(OH)$_2$D3).

| Equation                                    | Rate Equation |
|---------------------------------------------|---------------|
| $\frac{d[25(OH)D3]}{dt}$                   | $R_1 - R_2 - R_4 - R_5$ |
| $\frac{d[1,25(OH)_2D3]}{dt}$               | $R_2 - R_7$   |
| $\frac{d[24,25(OH)_2D3]}{dt}$              | $R_4 - R_8$   |
| $\frac{d[3-epi-25(OH)D3]}{dt}$             | $R_3 - R_8$   |
Table 8

Steady-state equations for reduced kinetic model of vitamin D metabolism.

Relationships between metabolite concentrations at steady-state for the reduced kinetic model of vitamin D metabolism, depicted in Fig. 2 are shown. Metabolites are listed with abbreviations in Table 3. Reaction parameters ($k_3 - k_8$, $K$, $a$, $p_{25(OH)D_3}$) as defined in the rate equations in Table 6. Concentrations and Michaelis constant $K$ are measured in nM. Non-catalytic rate constants ($k_3 - k_8$) are measured in d$^{-1}$. Base production constants ($P_{25(OH)D_3}$) and maximal enzyme rate ($a$) are measured in nM·d$^{-1}$.

\[
0 = [25(OH)D_3]^2 \cdot (k_3 + k_4 + k_5) \\
+ [25(OH)D_3] \cdot (K \cdot (k_3 + k_4 + k_5) + a - p_{25(OH)D_3}) \\
- (K \cdot p_{25(OH)D_3}).
\]  

(3.1a)

\[
[1, 25(OH)_2D_3] = \frac{a}{k_5} \cdot \frac{[25(OH)D_3]}{K + [25(OH)D_3]}.
\]  

(3.1b)

\[
[24, 25(OH)_2D_3] = \frac{k_4}{k_5} \cdot [25(OH)D_3]
\]  

(3.1c)

\[
[3 - epi - 25(OH)D_3] = \frac{k_3}{k_5} \cdot [25(OH)D_3]
\]  

(3.1d)
**Table 9**  
Summary of vitamin D metabolite ratios from the reduced kinetic model.

Metabolite ratios defined from the reduced kinetic model (Fig. 2) using steady state equations (Table 8). Michaelis constants $K$ are shown in nM and estimated value shown in Supplementary Table 4. Metabolites are listed with abbreviations in Table 3.

\[
\alpha = \frac{[1, 25(OH)\text{D}_3]}{[25(OH)\text{D}_3]} \cdot (K + [25(OH)\text{D}_3]) \quad (1\alpha\text{-hydroxylation}) \quad (3.2a)
\]
\[
\beta = \frac{[3 - \text{epi} - 25(\text{OH})\text{D}_3]}{[25(\text{OH})\text{D}_3]} \quad (\text{epimerisation}) \quad (3.2b)
\]
\[
\gamma = \frac{[24, 25(\text{OH})\text{D}_3]}{[25(\text{OH})\text{D}_3]} \quad (24\text{-hydroxylation}) \quad (3.2c)
\]